Academia.eduAcademia.edu

Serum hepcidin levels and stroke in thalassemia patients

2016, International journal of stroke : official journal of the International Stroke Society

Letter to the Editor International Journal of Stroke 2016, Vol. 11(4) NP50–NP51 ! 2016 World Stroke Organization Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1747493015623557 wso.sagepub.com Serum hepcidin levels and stroke in thalassemia patients Dear editor, Beta-thalassemia is a genetic disorder that is due to a reduced or complete absence of synthesis of b-globin chain in a molecule of hemoglobin. Burden with about 200 mg of iron per unit of packed red blood cells and moderately increased gastrointestinal uptake of iron due to the suppression of hepcidin1 leads to increased content of microelement in the body, which requires lifetime use of chelation therapy aimed to prevent or revers of related iron accumulation complications. In patients with thalassemia intermedia, there is a higher incidence of pulmonary hypertension and thrombosis.2,3 Iron overload is a result from repeated blood transfusions combined with increased gastrointestinal absorption in terms of ineffective erythropoiesis. Hepcidin is a peptide of 25 amino acids,4 whose main function is to inhibit the uptake of iron in plasma from three main sources: absorbed from food in the duodenum, recycled released by macrophages and released from landfills in hepatocytes.5 The formation of hepcidin is regulated by the concentration of the iron – in elevated iron concentration a large amounts hepcidin are secreted, which inhibits further iron absorption. The opposite occurs with iron deficiency – separation of hepcidin is reduced or stopped in order to be able to absorb a sufficient amount of microelement. Except in iron overload, the concentration of hepcidin increases in inflammation; it decreases in hypoxia. In b-thalassemia occurs very low hepcidin despite the excessive iron burden.6,7 It is believed that the reason for this dominance is the need of iron in erythropoiesis activated and tissue hypoxia. Samples were taken from 23 patients with thalassemia; 4 of them with stroke; average age 35.2  2.9. Their results were compared to 19 ischemic stroke cases; average age 41.9  3.5. We measure serum iron, hepcidin and ferritin levels. Pearson’s coefficient and Student’s t-test were used for evaluation of correlation and statistical significance. Patients were signing the informed consent according to the Declaration of Helsinki (Directive 2001/20/EC). International Journal of Stroke, 11(4) We found significant decreased hepcidin concentrations in thalassemia patients 0.95  0.2 mg/L. Patients with acute ischemic stroke showed elevated hepcidin levels 87.8  9.4 mg/L, (P < 0.001) (Figure 1). Serum iron levels were increased in both groups: 75.4  12.1 mmol/L in thalassemia vs. 29.4  2.8 mmol/ L in ischemic stroke, P < 0.001 (Figure 2). It is known that free iron increases significantly during ischemia and is responsible for oxidative damage in the brain. Increased hypoxia inducible factors leads to an oxidative stress, which plays an Figure 1. Serum hepcidin levels (in mg/L). Figure 2. Serum iron concentrations (in mmol/L). Petrova et al. important role in neuronal injuries caused by cerebral ischemia. The burden of iron overload in beta-thalassemia was unaffected by treatment with chelators, which can have severe side effects. There are a few studies about microhepcidin as an alternative of chelation therapy, especially in patients without transfusion therapy.8 Treatment with hepcidin may have a beneficial effect and ineffective erythropoiesis. Hepcidin measurement in cases of beta-thalassemia is important to determine whether transfusion treatment is effective in terms of ineffective erythropoiesis. It will avoid any further iron supplementation therapy in cases of microelement overload. NP51 7. Pasricha S, Frazer D, Bowden D and Anderson G. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major: a longitudinal study. Blood 2013; 122: 124–133. 8. Preza G, Ruchala P, Pinon R, et al. Minihepcidins are rationally designed small peptides that mimic hepidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest 2011; 121: 4880–4888. Julia Petrova Department of Neurology, Medical University, Sofia, Bulgaria Victor Manolov Department of Medical Genetics, Medical University, Sofia, Bulgaria Acknowledgments We kindly appreciate support for clinical laboratory evaluations from ‘‘Marvena’’ (‘‘Siemens Healthcare’’distributor in Bulgaria), and especially to Mr. Velizar Dragoev and Mrs. Silvia Kirova. Georgi Dimitrov, Rumiana Tarnovska-Kadreva and Theodora Yaneva-Sirakova Department of Cardiology, Medical University, Sofia, Bulgaria Declaration of conflicting interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project is implemented with the support of the Medical University – Sofia, as part of ‘‘Grant 2015’’. References 1. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007; 92: 583–588. 2. Aessopos A, Tsironi M, Andreopoulos A and Farmakis D. Heart disease in thalassemia intermedia. Hemoglobin 2009; 33(Suppl 1): S170–S176. 3. Musallam KM, Cappellini MD, Wood JC and Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev 2012; 26(Suppl 1): S16–S19. 4. Ganz T and Nemeth E. Hepcidin and iron homeostasis. Biochimia Biophysica Acta 2012; 1823: 1434–1443. 5. Park C, Valore E, Waring A and Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806–7810. 6. Nemeth E and Gan Z. Hepcidin and iron-loading anemias. Haematologica 2006; 91: 727–732. Milena Velizarova Department of Medical Genetics, Medical University, Sofia, Bulgaria Vasil Vasilev, Bisera Atanasova and Kamen Tzatchev Department of Clinical Laboratory and Clinical Immunology, Medical University, Sofia, Bulgaria Borislav Marinov University Hospital ‘‘Maichin Dom’’, Sofia, Bulgaria Radoslava Emilova Specialized Hospital for Active Treatment in Pediatrics, Sofia, Bulgaria Gencho Genchev Department of Health Economics, Faculty of Public Health, Medical University, Sofia, Bulgaria Corresponding author: Victor Manolov, Department of Medical Genetics, Medical University, 1 ‘‘Georgi Sofiiski’’ bul., 1431 Sofia, Bulgaria. Email: [email protected] International Journal of Stroke, 11(4)